Uniqure NV (QURE)

Currency in USD
47.970
-0.650(-1.34%)
Closed·
48.000+0.030(+0.06%)
·
QURE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
46.87048.500
52 wk Range
8.73071.500
Key Statistics
Prev. Close
48.62
Open
48.08
Day's Range
46.87-48.5
52 wk Range
8.73-71.5
Volume
838.63K
Average Volume (3m)
1.91M
1-Year Change
206.3218%
Book Value / Share
4.71
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
QURE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
69.787
Upside
+45.48%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Uniqure NV News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

11 Buy
1 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 69.787
(+45.48% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Wells Fargo
Buy75.00+56.35%60.00MaintainJul 30, 2026
Barclays
Buy60.00+25.08%65.00MaintainJul 30, 2026
Wolfe Research
Buy65.00+35.50%-UpgradeJul 29, 2026
H.C. Wainwright
Buy80.00+66.77%-MaintainJun 29, 2026
Mizuho
Buy68.00+41.76%35.00MaintainJun 25, 2026

Uniqure NV Earnings Call Summary for Q2/2026

  • uniQure reported Q2 revenue of $5.8M, up 9.4% YoY, beating estimates; EPS loss of $1.22 missed forecast of $0.84 by 45%.
  • FDA aligned on accelerated BLA pathway for AMT-130 Huntington's therapy using 3-year data; Q3 2026 submission planned with priority review.
  • Cash position strengthened to $810.3M from $622.5M, extending operational runway into 2030 to fund trials and commercial launch.
  • Stock surged 6.83% to $39.165 on regulatory progress despite earnings miss; confirmatory trial to use standard-of-care control arm.
  • SG&A expenses rose 28.9% to $17.4M for commercial prep; four-year AMT-130 data expected September 2026, UK filing on track for Q3.
Last Updated: 29/07/2026, 14:40
Read Full Transcript

Earnings

Latest Release
Jul 29, 2026
EPS / Forecast
-1.22 / -0.84
Revenue / Forecast
5.84M / 5.49M
EPS Revisions
Last 90 days

QURE Income Statement

Compare QURE to Peers and Sector

Metrics to compare
QURE
Peers
Sector
Relationship
P/E Ratio
−13.2x−1.8x−0.3x
PEG Ratio
2.710.110.00
Price/Book
10.3x2.7x2.6x
Price / LTM Sales
178.2x9.6x3.1x
Upside (Analyst Target)
46.1%160.0%49.0%
Fair Value Upside
Unlock10.7%6.3%Unlock

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
21.09M30.40%1.03B
Other Institutional Investors
39.27M56.61%1.91B
Public Companies & Retail Investors
9.01M12.99%438.22M
Total
69.37M100.00%3.37B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Avoro Capital Advisors LLC8.59%5,959,595289,756
State Street Investment Management4.19%2,903,825141,184

People Also Watch

95.970
AXTI
+17.55%
968.90
LITE
+4.62%
234.33
MRVL
+5.54%
351.22
COHR
+7.79%
13.410
INFQ
+4.28%

FAQ

What Is the Uniqure NV (QURE) Stock Price Today?

The Uniqure NV stock price today is 47.970 USD.

What Stock Exchange Does Uniqure NV Trade On?

Uniqure NV is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Uniqure NV?

The stock symbol for Uniqure NV is "QURE."

What Is the Uniqure NV (QURE) Afterhours Price Today? (Afterhours variable test: 48.000) Current Date: Aug 18, 2026

After hours price: 48.000. After hours price change (units): 0.030. Price change percentage: 0.060%

What Is the Uniqure NV Market Cap?

As of today, Uniqure NV market cap is 3.330B USD.

What Is Uniqure NV's Earnings Per Share (TTM)?

The Uniqure NV EPS (TTM) is -4.036.

When Is the Next Uniqure NV Earnings Date?

Uniqure NV will release its next earnings report on Nov 10, 2026.

From a Technical Analysis Perspective, Is QURE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Uniqure NV Stock Split?

Uniqure NV has split 0 times.

How Many Employees Does Uniqure NV Have?

Uniqure NV has 221 employees.

What is the current trading status of Uniqure NV (QURE)?

As of Aug 18, 2026, Uniqure NV (QURE) is trading at a price of 47.970 USD, with a previous close of 48.620 USD. The stock has fluctuated within a day range of 46.870 USD to 48.500 USD, while its 52-week range spans from 8.730 USD to 71.500 USD.

What Is Uniqure NV (QURE) Price Target According to Analysts?

The average 12-month price target for Uniqure NV is 69.787 USD, with a high estimate of 96.7331481 USD and a low estimate of 46.83869624 USD. 11 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +45.48% Upside potential.

What Is the QURE Premarket Price?

QURE's last pre-market stock price is 47.550 USD. The pre-market share volume is 6,460.000, and the stock has decreased by -1.070, or -2.200%.

What Is the QURE After Hours Price?

QURE's last after hours stock price is 48.000 USD, the stock has decreased by 0.030, or 0.060%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.